Sun Pharma, Incyte and Leqselvi

Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi
Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and | Sun Pharma,
Incyte blocks US launch of Sun Pharma's alopecia drug
Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) it holds on the use of ruxolitinib, a JAK inhibitor it sells as Jakafi to treat various haematological cancers and in a topical form as Opzelura for atopic dermatitis and vitiligo.
Sun Pharma's Leqselvi launch in US faces legal roadblock; analysts cautious
This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company wins its appeal, or up to two years if it loses the case entirely
Sun Pharma’s hair loss drug Leqselvi's launch remains in limbo
Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for a launch in July-August as per reports.
Sun Pharma alopecia drug Leqselvi launch blocked in US
Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.
Sun Pharma share price plunges 5% after US ruling on Leqselvi launch - Here's what JPMorgan, UBS say
After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged over 5 per cent on Monday, November 04. Read on to know what UBS and JPMorgan said on the situation.
Sun Pharma shares slump 5% after US court ruling stalls Leqselvi launch
In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.
Sun Pharma shares fall 5% post Leqselvi injunction, but analysts say opportunity 'not over'
According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term earnings by 3-6% of EPS and may also affect competitive positioning, as rival drugs will have longer-term clinical data by the time Sun's ...
Sun Pharma declines 2.64% after US Court delays Leqselvi launch
Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major recently announced that the US District Court of delayed the launch of its new drug - Leqselvi. According to
Sun Pharma shares in focus as US court blocks Leqselvi launch
Sun Pharma faces a delay in the U.S. launch of its drug Leqselvi due to a preliminary injunction by the New Jersey court, pending further legal proceedings or patent expiration in December 2026. The company plans to appeal the decision while considering a potential settlement with Incyte.
Sun Pharma: Down but not out?
How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?
Hot stocks: Brokerage view on M&M, Nykaa and Sun Pharma
JPMorgan reports that Sun Pharma plans to appeal a judgment and may seek a settlement with Incyte to expedite its product ...
FiercePharma18h
Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs
To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...